Peringatan Keamanan

The most frequent adverse events associated with eptinezumab use include upper respiratory tract infection, urinary tract infection, fatigue, back pain, arthralgia, and nausea and vomiting A33108. No data regarding overdosage has been reported yet.

Eptinezumab

DB14040

biotech approved investigational

Deskripsi

Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals.L12318 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).F94,A33105,A33106,A33108 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.L12318

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The plasma half-life after an intravenous infusion is approximately 27 days.[L12318]
Volume Distribusi The central volume of distribution for eptinezumab is approximately 3.7 L.[L12318]
Klirens (Clearance) The apparent clearance of eptinezumab is 0.006 L/h.[L12318]

Absorpsi

Eptinezumab is the only potent and selective and anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered by quarterly infusion for migraine prevention delivering 100% bioavailability by way of the intravenous route of administration to immediately inhibit CGRP .L2825 With an intravenous dose of eptinezumab 1000 mg, the mean maximum concentration of 336.4 ug/mL (SD 79.9) occurred after 4.8 hours after the start of the 1 hour infusion A33108. The mean exposure to free eptinezumab, as characterized by area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and from time zero to infinity were 8245 days per ug per mL (SD 2619) and 8722 days per ug per mL (SD 2522), respectively A33108.

Metabolisme

Monoclonal antibody agents like eptinezumab are not expected to generate toxic metabolites as they generally undergo proteolysis to their constituent amino acids.F94

Rute Eliminasi

Monoclonal antibody agents like eptinezumab are generally not eliminated via hepatic, renal, or biliary routes.F94

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Eptinezumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Eptinezumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Eptinezumab.
Estrone Estrone may increase the thrombogenic activities of Eptinezumab.
Estradiol Estradiol may increase the thrombogenic activities of Eptinezumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Eptinezumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Eptinezumab.
Mestranol Mestranol may increase the thrombogenic activities of Eptinezumab.
Estriol Estriol may increase the thrombogenic activities of Eptinezumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Eptinezumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Eptinezumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Eptinezumab.
Tibolone Tibolone may increase the thrombogenic activities of Eptinezumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eptinezumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eptinezumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Eptinezumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Eptinezumab.
Zeranol Zeranol may increase the thrombogenic activities of Eptinezumab.
Equol Equol may increase the thrombogenic activities of Eptinezumab.
Promestriene Promestriene may increase the thrombogenic activities of Eptinezumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Eptinezumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Eptinezumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Eptinezumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Eptinezumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Eptinezumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Eptinezumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Eptinezumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Eptinezumab.
Formononetin Formononetin may increase the thrombogenic activities of Eptinezumab.
Estetrol Estetrol may increase the thrombogenic activities of Eptinezumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Eptinezumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Eptinezumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Eptinezumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Eptinezumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eptinezumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Eptinezumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Eptinezumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eptinezumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Eptinezumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Eptinezumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eptinezumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Eptinezumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Eptinezumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eptinezumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Eptinezumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Eptinezumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Eptinezumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Eptinezumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Eptinezumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Eptinezumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Eptinezumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Eptinezumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Eptinezumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Eptinezumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Eptinezumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Eptinezumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Eptinezumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Eptinezumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Eptinezumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eptinezumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Eptinezumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Eptinezumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Eptinezumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Eptinezumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Eptinezumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Eptinezumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Eptinezumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eptinezumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Eptinezumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Eptinezumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eptinezumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eptinezumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Eptinezumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Eptinezumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Eptinezumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Eptinezumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Eptinezumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Eptinezumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Eptinezumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Eptinezumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Eptinezumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Eptinezumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eptinezumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Eptinezumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Eptinezumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Eptinezumab.

Target Protein

Calcitonin gene-related peptide 1 CALCA
Calcitonin gene-related peptide 2 CALCB

Referensi & Sumber

Artikel (PubMed)
  • PMID: 28409893
    Pellesi L, Guerzoni S, Pini LA: Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clin Pharmacol Drug Dev. 2017 Nov;6(6):534-547. doi: 10.1002/cpdd.345. Epub 2017 Apr 14.
  • PMID: 29019093
    Benemei S, Cortese F, Labastida-Ramirez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M: Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. 2017 Oct 10;18(1):103. doi: 10.1186/s10194-017-0811-5.
  • PMID: 25297013
    Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5.
  • PMID: 28948500
    Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A: Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96. doi: 10.1186/s10194-017-0807-1.
  • PMID: 24867844
    Vollbracht S, Rapoport AM: New treatments for headache. Neurol Sci. 2014 May;35 Suppl 1:89-97. doi: 10.1007/s10072-014-1747-z.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Vyepti
    Injection, solution, concentrate • 300 mg • Intravenous • EU • Approved
  • Vyepti
    Injection • 100 mg/1mL • Intravenous • US • Approved
  • Vyepti
    Solution • 300 mg / 3 mL • Intravenous • Canada • Approved
  • Vyepti
    Injection, solution, concentrate • 100 mg • Intravenous • EU • Approved
  • Vyepti
    Solution • 100 mg / mL • Intravenous • Canada • Approved
  • Vyepti
    Injection, solution, concentrate • 100 mg • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul